---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-065229"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2024-05-28T23:59:59+00:00"
generated_at: "2026-06-01T07:56:23.735571+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma appoints new CFO, shareholders approve share increase and reverse split authority

## Summary
- Mark A. Kowieski appointed CFO effective May 22, 2024; annual base salary $390,000, target bonus 40%.
- CEO Matthew D'Onofrio base salary raised to $615,000, target bonus to 60%.
- Shareholders approved increase in authorized common shares from 50M to 100M.
- Shareholders approved amendment to 2013 Equity Incentive Award Plan, adding 4M shares plus evergreen provision (up to 6% of outstanding annually).
- Shareholders granted Board authority to effect reverse stock split within 1 year, range 1:2 to 1:20.

## SEC filing metadata
- accession: 0000950170-24-065229
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2024-05-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.03, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/0000950170-24-065229-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/evok-20240522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-065229
- JSON: https://secwatch.observer/filing/0000950170-24-065229.json
- Plain text: https://secwatch.observer/filing/0000950170-24-065229.txt

## Key facts
- Executive change
  Mark A. Kowieski was appointed as Chief Financial Officer at Evoke Pharma Inc.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On May 22, 2024, the Board appointed Mr. Kowieski, age 47, as Chief Financial Officer ("CFO") of Evoke Pharma, Inc. (the "Company") effective May 22, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017024065229/0000950170-24-065229-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.